Clinical trials: Hepatic Carcinoma
Hepatocellular Carcinoma, Hepatoma
Accuracy of Endoscopic Ultrasound for Detection of Tumors of the Liver
The diagnostic accuracy of EUS for detection of the liver tumors (primary and metastatic) remains unknown. To compare the accuracy of the EUS and CT scan for detection of the primary and metastatic carcinoma of the liver.
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Cholangiocarcinoma, Liver Metastases
- Trial name
- NCT00290316
- Testing
- Endoscopy ultrasound
- Where
- United States
- Sponsor
- Central Texas Veterans Health Care System
Liver Carcinoma, Hepatocellular Carcinoma
Combined HCC-MFCCC
Combined hepatocellular and mass-forming cholangiocarcinoma (cHCC-MFCCC) is a rare tumor. The aim of this study was the analysis of the outcome comparing such tumor with classic hepatocellular carcinoma (HCC) and mass-forming…
- Conditions
- Liver Carcinoma, Hepatocellular Carcinoma, Cholangiocarcinoma, Surgery
- Trial name
- NCT03178409
- Testing
- Hepatectomy
- Volunteers
- 100 people
- Sponsor
- University of Milan
Liver Cancer, Hepatocellular Carcinoma
Effect of a Perioperative Oral Nutritional Supplementation on Patients Undergoing Hepatic Surgery for Liver Cancer
Cirrhotic patients undergoing hepatic resection have a mortality rate near 10%, and 30 to 70% of them develop severe complications. These failures are mainly due to hepatic insufficiency.
- Conditions
- Liver Cancer, Hepatocellular Carcinoma, Cirrhosis, Liver Fibrosis
- Trial name
- IMPACT (NCT00151671)
- Testing
- Oral Impact®
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Rennes University Hospital
HCC
Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma
Donafenib versus sorafenib for advanced hepatocellular cancer.
- Trial name
- NCT02645981
- Testing
- Donafenib, Sorafenib
- Where
- 2 sites in China
- Volunteers
- 668 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Hepatocellular Carcinoma, Radiation Exposure
Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC)…
- Trial name
- NCT03686709
- Testing
- Post therapy PET/CT Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Tennessee
Carcinoma, Hepatocellular, Neuroendocrine Tumors
Circulating Tumor Cells and Tumor DNA in HCC and NET
Background Treatment and control of cancer is associated with high costs, to patients in the form of side effects and discomfort during investigations, to society in the form of expensive drugs and studies.
- Trial name
- NCT02973204
- Testing
- Sorafenib, Radiofrequency ablation (RFA) or surgery, Everolimus
- Where
- Denmark
- Volunteers
- 167 people
- Sponsor
- University of Aarhus
Carcinoma, Hepatocellular
Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
CC-122-HCC-001 is a Phase 1b dose escalation and expansion clinical study of CC-122 in combination with sorafenib for subjects with unresectable HCC who have received no prior systemic therapy for HCC.
- Trial name
- NCT02323906
- Testing
- CC-122, Sorafenib
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- Celgene
Hepatocellular Carcinoma, Liver Cancer
TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma
The purpose of this protocol is to provide TheraSphere treatment for patients with liver cancer who cannot be treated by surgery. The effect on the tumor and any side effects of TheraSphere treatment will be examined.
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasm, Primary Liver Cancer
- Trial name
- TheraSphere (NCT00906984)
- Testing
- TheraSphere
- Where
- United States
- Sponsor
- University of California, Irvine
Hepatocellular Carcinoma
AFP- L3% and DCP as Tumor Markers in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolisation (TACE)
Hepatocellular carcinoma (HCC) is one of the tumors with an increasing incidence worldwide. Often treatment possibilities are limited and only palliative treatment such as a transarterial chemoembolisation (TACE) is possible.
- Trial name
- NCT01360255
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- University Hospital Freiburg
Carcinoma, Hepatocellular
Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria
This study is designed to determine whether proton beam radiotherapy plus Sorafenib compared to Sorafenib alone will produce the best results for treating patients with Hepatocellular Carcinoma.
- Trial name
- HCC (NCT01141478)
- Testing
- Proton Beam Radiotherapy, Sorafenib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Loma Linda University
Hepatocellular Carcinoma (HCC)
Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma
A Study of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients with Unresectable Recurrent/Metastatic Hepatocellular Carcinoma.
- Trial name
- NCT07487402
- Testing
- Metabolically Armed GPC3 CAR-T cells
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Zhejiang University
Carcinoma
Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.
The purpose of this study is to compare treatment with RAD001 plus best supportive care (BSC) to placebo plus BSC in patients with advanced HCC whose disease progressed while on or after sorafenib treatment or who are intolerant…
- Trial name
- EVOLVE-1 (NCT01035229)
- Testing
- Everolimus, Best Supportive Care (BSC)
- Where
- 131 sites in United States, Australia and 16 more
- Volunteers
- 546 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma, Laser Ablation
Laser Ablation for Intermediate and Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Hepatocellular carcinoma (HCC) is the fifth most-common cancer worldwide and the second most-common cause of cancer mortality. Liver resection is the first-line curative treatment for huge HCC.
- Conditions
- Hepatocellular Carcinoma, Laser Ablation, Portal Vein Tumor Thrombus
- Trial name
- NCT02724475
- Testing
- LA, 3D-CRT
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Cancer, Pancreatic Cancer
High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors
This is an open, prospective, single-arm, multi-cohort clinical study to evaluate the efficacy and safety of high-dose vitamin C combined with metformin in the treatment of malignant tumors.
- Conditions
- Hepatocellular Cancer, Pancreatic Cancer, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT04033107
- Testing
- Vitamin C, Metformin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhongnan Hospital
Cancer of the Liver
Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract
To evaluate objective response rate and duration of response to weekly Taxoprexin®. To evaluate the safety profile of weekly Taxoprexin® in this patient population. To evaluate overall survival in the same patient population.
- Trial name
- NCT00422877
- Testing
- Taxoprexin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- American Regent, Inc.
Hepatocellular Carcinoma, Liver Transplantation
A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Hepatocellular Carcinoma Beyond UCSF Criteria Before Liver Transplantation
This is a single-center, retrospective cohort study aiming to evaluate the safety and efficacy of a combined treatment strategy for patients with hepatocellular carcinoma (HCC) who are beyond the UCSF criteria but intended for…
- Trial name
- NCT07310836
- Testing
- Locoregional Therapy (LRT) + Systemic Drug Therapy
- Volunteers
- 300 people
- Sponsor
- Ningbo Medical Center Lihuili Hospital
Cirrhosis, Liver, Hepatocellular Carcinoma
CT-guided Localization for Micro Hepatocellular Carcinoma Before Surgical Resection
In this project, the preoperative anatomical location of micro hepatocellular carcinoma under the guidance of CT can provide guidance for accurate surgical resection.
- Trial name
- CTMH (NCT05433467)
- Testing
- CT-guided localization for micro hepatocellular carcinoma before surgical resection
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Northern Jiangsu People's Hospital
Advanced Adult Primary Liver Cancer, Liver Metastases
Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
This pilot clinical trial studies positron emission tomography (PET)/computed tomography (CT) in finding beads after Yttrium-90 bead therapy in patients with primary liver cancer or cancer that has spread to the liver…
- Conditions
- Advanced Adult Primary Liver Cancer, Liver Metastases, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT02119065
- Testing
- positron emission tomography, computed tomography
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Cincinnati
Hepatocellular Carcinoma, Nonalcoholic Steatohepatitis
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver.
- Trial name
- NCT04550481
- Testing
- Biospecimen Collection, Lisinopril, Liver Ultrasonographic Elastography
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Northwestern University
Liver Cancer
Multicentre Prospective Clinical Trial for RFA Tumour Aspirator Treatment of Primary and Secondary Malignancies of the Liver
The primary aim for this trial is to assess whether the RFA aspirator device is safe and of clinical benefit in patients with primary or secondary malignant liver tumours
- Trial name
- NCT00514930
- Testing
- Hexablate
- Where
- Greece
- Sponsor
- University of Thessaly